Investors may have missed OncoMed Pharmaceuticals (OMED) in the flurry of biotech IPOs this year, but last week's pop was more than enough to raise a few eyebrows. Shares soared more than 80% after the company announced a deal with big biotech Celgene (CELG). In the following video, analysts Simon Erickson and Max Macaluso discuss the details of the deal, what it means for both OncoMed and Celgene, and whether partnerships like this will be a continuing trend in the biotech space.
S&P 500
5,970.81
+0.0%
+$0.44
DJI
42,427.74
-0.2%
-$91.90
NASDAQ
19,460.49
+0.3%
+$61.53
Bitcoin
104,661.00
-1.0%
-1,088.71
AAPL
$202.99
-0.1%
-$0.28
AMZN
$207.37
+0.8%
+$1.66
GOOG
$169.50
+1.1%
+$1.79
META
$687.21
+3.1%
+$20.36
MSFT
$464.20
+0.3%
+$1.23
NVDA
$141.94
+0.5%
+$0.72
TSLA
$333.21
-3.2%
-$11.06
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.